Author

Lin Xu

h-index 10 View on Semantic Scholar

We have 2 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

AI-driven dual-task prediction model for co-stratifying efficacy and toxicity in NSCLC immunotherapy

While effective against non-small cell lung cancer (NSCLC), PD-1 inhibitors can induce immune-related adverse events (irAEs), occurring in up to 15.2% of patients and potentially fatal. Currently, effective predictive biomarkers capable of simultaneously forecasting both irAEs and immune checkpoint inhibitor (ICI) resp...

Hanlin Ding, Yu-Ting Ren, Siqi Ding et al. · PLOS Digital Health · 0 citations

Open access Jul 2026

Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis.

DLX6 is significantly upregulated in LUAD and offers a potential therapeutic target for sensitizing cisplatin treatment and improving chemotherapy resistance and highlights DLX6 as a key regulator of ferroptosis and cisplatin sensitivity in LUAD.

Zedong Sun, Minmin Zhou, Can Wang et al. · Cellular Oncology · 0 citations